Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "F. Stephen Hodi" Clear advanced filters

  • In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immune response are now key to further advances. Several studies published in 2015 have increased our understanding of the complex relationships that exist between our immune system and malignancy.

    • Elizabeth I. Buchbinder
    • F. Stephen Hodi
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 13, P: 77-78

  • Patients receiving anticancer therapies based on immune-checkpoint blockade (ICB) often experience clinical benefits from such treatments, but unconventional patterns of response can be observed, emphasizing the importance of using a specific approach to evaluating responses to immunotherapy. Herein, the authors review the biological mechanisms underlying the response patterns associated with ICB, describe strategies for the assessments of such responses, and highlight the ongoing efforts to identify biomarkers to guide treatment with ICB.

    • Mizuki Nishino
    • Nikhil H. Ramaiya
    • F. Stephen Hodi
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 14, P: 655-668

  • Immunotherapy is associated with durable clinical benefit in patients with melanoma, and this consensus statement outlines recommendations for its use. The panel has based their guidance on the available evidence and outlines a treatment paradigm using drugs that are FDA approved.

    • Howard L. Kaufman
    • John M. Kirkwood
    • Michael B. Atkins
    ReviewsOpen Access
    Nature Reviews Clinical Oncology
    Volume: 10, P: 588-598

  • There are multiple subclasses of melanoma that are partly categorized on the basis of their oncogenic molecular drivers. As discussed in this Review, the understanding of the molecular features of melanoma has led to several exciting advances in the treatment of patients with melanoma.

    • Keith T. Flaherty
    • F. Stephen Hodi
    • David E. Fisher
    Reviews
    Nature Reviews Cancer
    Volume: 12, P: 349-361